Manufacturer of Controlled Substances; Notice of Application, 61911-61912 [E8-24772]
Download as PDF
<![CDATA[
61911
Federal Register / Vol. 73, No. 202 / Friday, October 17, 2008 / Notices
Drug
Schedule
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to manufacture
small quantities of the listed controlled
substances to make reference standards
which will be distributed to their
customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than December 16, 2008.
sroberts on PROD1PC70 with NOTICES
Pentobarbital (2270) ....................................................................................................................................................................................
Secobarbital (2315) .....................................................................................................................................................................................
Glutethimide (2550) .....................................................................................................................................................................................
Nabilone (7379) ...........................................................................................................................................................................................
1-Phenylcyclohexylamine (7460) .................................................................................................................................................................
Phencyclidine (7471) ...................................................................................................................................................................................
1-Piperidinocyclohexanecarbonitrile (8603) ................................................................................................................................................
Alphaprodine (9010) ....................................................................................................................................................................................
Cocaine (9041) ............................................................................................................................................................................................
Codeine (9050) ............................................................................................................................................................................................
Dihydrocodeine (9120) ................................................................................................................................................................................
Oxycodone (9143) .......................................................................................................................................................................................
Hydromorphone (9150) ...............................................................................................................................................................................
Diphenoxylate (9170) ..................................................................................................................................................................................
Benzoylecgonine (9180) ..............................................................................................................................................................................
Ethylmorphine (9190) ..................................................................................................................................................................................
Hydrocodone (9193) ....................................................................................................................................................................................
Levomethorphan (9210) ..............................................................................................................................................................................
Levorphanol (9220) .....................................................................................................................................................................................
Isomethadone (9226) ..................................................................................................................................................................................
Meperidine (9230) .......................................................................................................................................................................................
Meperidine intermediate-A (9232) ...............................................................................................................................................................
Meperidine intermediate-B (9233) ...............................................................................................................................................................
Meperidine intermediate-C (9234) ...............................................................................................................................................................
Methadone (9250) .......................................................................................................................................................................................
Methadone intermediate (9254) ..................................................................................................................................................................
Dextropropoxyphene, bulk (non-dosage forms) (9273) ..............................................................................................................................
Morphine (9300) ..........................................................................................................................................................................................
Thebaine (9333) ..........................................................................................................................................................................................
Levo-alphacetylmethadol (9648) .................................................................................................................................................................
Oxymorphone (9652) ...................................................................................................................................................................................
Noroxymorphone (9668) ..............................................................................................................................................................................
Racemethorphan (9732) ..............................................................................................................................................................................
Alfentanil (9737) ..........................................................................................................................................................................................
Sufentanil (9740) .........................................................................................................................................................................................
Fentanyl (9801) ...........................................................................................................................................................................................
Schedule
Dated: October 9, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–24771 Filed 10–16–08; 8:45 am]
BILLING CODE 4410–09–P
VerDate Aug<31>2005
19:18 Oct 16, 2008
Jkt 217001
DEPARTMENT OF JUSTICE
Drug
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on July 15, 2008,
Noramco Inc., 1440 Olympic Dr.,
Athens, Georgia 30601, made
application by renewal to the Drug
Enforcement Administration (DEA) as a
bulk manufacturer of the basic classes of
controlled substances listed in
schedules I and II:
Drug
Schedule
Codeine-N-Oxide (9053) ..............
Morphine-N-Oxide (9307) .............
Amphetamine (1100) ....................
Methylphenidate (1724) ................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Hydrocodone (9193) .....................
Morphine (9300) ...........................
Oripavine (9330) ...........................
Thebaine (9333) ...........................
Oxymorphone (9652) ...................
Alfentanil (9737) ...........................
PO 00000
Frm 00135
Fmt 4703
Sfmt 4703
I
I
II
II
II
II
II
II
II
II
II
II
II
II
Sufentanil (9740) ..........................
Carfentanil (9743) .........................
Fentanyl (9801) ............................
II
II
II
The company plans to manufacture
small quantities of the schedule I
controlled substances for internal
testing; the schedule II controlled
substances will be manufactured in bulk
for distribution to its customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than December 16, 2008.
E:\FR\FM\17OCN1.SGM
17OCN1
61912
Federal Register / Vol. 73, No. 202 / Friday, October 17, 2008 / Notices
Dated: October 9, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–24772 Filed 10–16–08; 8:45 am]
DEPARTMENT OF JUSTICE
BILLING CODE 4410–09–P
By Notice dated June 20, 2008, and
published in the Federal Register on
June 27, 2008, (73 FR 36573),
Archimica, Inc., 2460 W. Bennett Street,
Springfield, Missouri 65807–1229, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedule II:
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on August 5, 2008,
Cayman Chemical Company, 1180 East
Ellsworth Road, Ann Arbor, Michigan
48108, made application by renewal to
the Drug Enforcement Administration
(DEA) as a bulk manufacturer of the
basic classes of controlled substances
listed in schedule I:
Drug
Schedule
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
I
I
sroberts on PROD1PC70 with NOTICES
The company plans to manufacture
small quantities of marihuana
derivatives for research purposes. In
reference to drug code 7360
(Marihuana), the company plans to bulk
manufacture cannabidiol. In reference to
drug code 7370
(Tetrahydrocannabinols), the company
will manufacture a synthetic THC. No
other activity for this drug code is
authorized for registration.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than December 16, 2008.
Dated: October 9, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–24773 Filed 10–16–08; 8:45 am]
BILLING CODE 4410–09–P
VerDate Aug<31>2005
19:18 Oct 16, 2008
Jkt 217001
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
Drug
Schedule
Methylphenidate (1724) ................
Phenylacetone (8501) ..................
Methadone Intermediate (9254) ...
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for research purposes, and sale to its
customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Archimica, Inc. to manufacture the
listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Archimica, Inc. to ensure
that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: October 9, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–24775 Filed 10–16–08; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated April 28, 2008, and
published in the Federal Register on
May 2, 2008, (73 FR 24313), Abbott
PO 00000
Frm 00136
Fmt 4703
Sfmt 4703
Laboratories, DBA Knoll Pharmaceutical
Company, 30 North Jefferson Road,
Whippany, New Jersey 07981, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedules I and II:
Drug
Dihydromorphine (9145) ...............
Hydromorphone (9150) ................
Schedule
I
II
The company plans to manufacture
bulk product and dosage units for
distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Abbott Laboratories to manufacture the
listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Abbott Laboratories to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: October 9, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E8–24777 Filed 10–16–08; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF LABOR
Mine Safety and Health Administration
Petitions for Modification
Mine Safety and Health
Administration, Labor.
ACTION: Notice of petitions for
modification of existing mandatory
safety standards.
AGENCY:
SUMMARY: Section 101(c) of the Federal
Mine Safety and Health Act of 1977 and
30 CFR Part 44 govern the application,
processing, and disposition of petitions
for modification. This notice is a
summary of petitions for modification
filed by the parties listed below to
modify the application of existing
E:\FR\FM\17OCN1.SGM
17OCN1
]]>Agencies
[Federal Register Volume 73, Number 202 (Friday, October 17, 2008)]
[Notices]
[Pages 61911-61912]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-24772]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on July 15, 2008, Noramco Inc.,
1440 Olympic Dr., Athens, Georgia 30601, made application by renewal to
the Drug Enforcement Administration (DEA) as a bulk manufacturer of the
basic classes of controlled substances listed in schedules I and II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Codeine-N-Oxide (9053)..................... I
Morphine-N-Oxide (9307).................... I
Amphetamine (1100)......................... II
Methylphenidate (1724)..................... II
Codeine (9050)............................. II
Dihydrocodeine (9120)...................... II
Oxycodone (9143)........................... II
Hydromorphone (9150)....................... II
Hydrocodone (9193)......................... II
Morphine (9300)............................ II
Oripavine (9330)........................... II
Thebaine (9333)............................ II
Oxymorphone (9652)......................... II
Alfentanil (9737).......................... II
Sufentanil (9740).......................... II
Carfentanil (9743)......................... II
Fentanyl (9801)............................ II
------------------------------------------------------------------------
The company plans to manufacture small quantities of the schedule I
controlled substances for internal testing; the schedule II controlled
substances will be manufactured in bulk for distribution to its
customers.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substances, may file comments
or objections to the issuance of the proposed registration pursuant to
21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than December 16, 2008.
[[Page 61912]]
Dated: October 9, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E8-24772 Filed 10-16-08; 8:45 am]
BILLING CODE 4410-09-P
